ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver Disease

Lu, Huanfen; Ban, Zhenglan; Xiao, Kai; Sun, Madi; Liu, Yongbo; Chen, Fangman; Shi, Tongfei; Chen, Li; Shao, Dan*; Zhang, Ming*; Li, Wei*吉林大学
Advanced Science2024-1-9DOI: 10.1002/advs.202308866
10阅读
引用收藏
分享

摘要

Exploration of medicines for efficient and safe management of metabolic-associated fatty liver disease (MAFLD) remains a challenge. Obeticholic acid (OCA), a selective farnesoid X receptor agonist, has been reported to ameliorate injury and inflammation in various liver diseases. However, its clinical application is mainly limited by poor solubility, low bioavailability, and potential side effects. Herein a hepatic-targeted nanodrugs composed of OCA and cholesterol-lowering atorvastatin (AHT) with an ideal active pharmaceutical ingredient (API) content for orally combined treatment of MAFLD is created. Such carrier-free nanocrystals (OCAHTs) are self-assembled, not only improving the stability in gastroenteric environments but also achieving hepatic accumulation through the bile acid transporter-mediated enterohepatic recycling process. Orally administrated OCAHT outperforms the simple combination of OCA and AHT in ameliorating of liver damage and inflammation in both acetaminophen-challenged mice and high-fat diet-induced MAFLD mice with less systematic toxicity. Importantly, OCAHT exerts profoundly reverse effects on MAFLD-associated molecular pathways, including impairing lipid metabolism, reducing inflammation, and enhancing the antioxidation response. This work not only provides a facile bile acid transporter-based strategy for hepatic-targeting drug delivery but also presents an efficient and safe full-API nanocrystal with which to facilitate the practical translation of nanomedicines against MAFLD. @@@ A hepatic-targeted nanodrug composed of obeticholic acid (OCA) and atorvastatin (AHT) is created to improve the stability in gastroenteric environments, while leveraging hepatic accumulation through apical sodium-dependent bile acid transporter. Oral administration of the nanodrug outperforms the simple combination of OCA and AHT in ameliorating liver damage and inflammation in mice with acute liver injury or metabolic-associated fatty liver disease.image

学科与关键词

关键词
atorvastatininflammationmetabolic-associated fatty liver diseasenanocrystalobeticholic acid
相关
加载中…
  • Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
    Lin, Chuangzhen; Yu, Bingqing; Chen, Lixin; Zhang, Zhaohui; Ye, Weixiang; Zhong, Hui; Bai, Wenke; Yang, Yuping; Nie, Biao*Frontiers in Pharmacology, 2022, 13: 880508.被引 5
  • Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse
    Lin, Chuangzhen; Yu, Bingqing; Liu, Xuelian; Chen, Lixin; Zhang, Zhaohui; Ye, Weixiang; Zhong, Hui; Bai, Wenke; Yang, Yuping; Nie, Biao*Biomedicine and Pharmacotherapy, 2022, 150: 112984.被引 2
  • Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis
    Cao, Shengtian; Yang, Xinye; Zhang, Zheng; Wu, Junwen; Chi, Bo; Chen, Hong; Yu, Jianghong; Feng, Shanshan; Xu, Yulin; Li, Jing; Zhang, Yingjun; Wang, Xiaojun*; Wang, Yan*European Journal of Medicinal Chemistry, 2022, 230: 114089.被引 9
查看全部 →

发表信息

论文状态
公开发表
期刊
Advanced Science
发表日期
2024-01-09
DOI
10.1002/advs.202308866
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities; [82104465]

作者

  • L

    Lu, Huanfen (第一作者)

  • B

    Ban, Zhenglan

查看全部 11 位作者收起作者
  • X

    Xiao, Kai

  • S

    Sun, Madi

  • L

    Liu, Yongbo

    jilin agr univ

  • C

    Chen, Fangman

  • S

    Shi, Tongfei

  • C

    Chen, Li

    jilin univ

  • S

    Shao, Dan (通讯)

  • Z

    Zhang, Ming (通讯)

    jilin univ

  • L

    Li, Wei (通讯)

    jilin agr univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417